Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sherry Xueyu Liu"'
Autor:
Michael Davidson, Sherry Xueyu Liu, Philip Barter, Eliot A. Brinton, Christopher P. Cannon, Antonio M. Gotto, Jr., Elizabeth T. Leary, Sukrut Shah, Michael Stepanavage, Yale Mitchel, Hayes M. Dansky
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 2, Pp 467-472 (2013)
Estimation of low-density lipoprotein cholesterol (LDL-C) using the Friedewald (FR) formula is often inaccurate when triglycerides are elevated or VLDL particle composition is altered. We hypothesized that LDL-C estimation by the FR formula and other
Externí odkaz:
https://doaj.org/article/6a2fcbd9ba29424f83ed05a6e6cfc2d9
Autor:
Christopher P, Cannon, Sukrut, Shah, Hayes M, Dansky, Michael, Davidson, Eliot A, Brinton, Antonio M, Gotto, Michael, Stepanavage, Sherry Xueyu, Liu, Patrice, Gibbons, Tanya B, Ashraf, Jennifer, Zafarino, Yale, Mitchel, Philip, Barter, T O, Wahl
Publikováno v:
The New England journal of medicine
Background Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. Methods We conducted a randomized, double-blind, placebo-controlled
Autor:
Christopher P, Cannon, Hayes M, Dansky, Michael, Davidson, Antonio M, Gotto, Eliot A, Brinton, A Lawrence, Gould, Michael, Stepanavage, Sherry Xueyu, Liu, Sukrut, Shah, Joseph, Rubino, Patrice, Gibbons, Anne, Hermanowski-Vosatka, Bruce, Binkowitz, Yale, Mitchel, Philip, Barter, Andrew, Tonkin
Publikováno v:
American heart journal, 158(4), 513-519.e3. Mosby Inc.
American heart journal
American heart journal
Background Residual cardiovascular (CV) risk often remains high despite statin therapy to lower low-density lipoprotein cholesterol (LDL-C). New therapies to raise high-density lipoprotein cholesterol (HDL-C) are currently being investigated. Anacetr